 The purpose of this 2-arm randomized controlled trial RCT is to evaluate the efficacy of Multi-Component Mobile-enhanced Treatment for Smoking Cessation iCOMMIT in helping individuals with schizophrenia or other psychotic disorders stop smoking. Eligible participants will be randomized to receive iCOMMIT, which includes smoking cessation counseling, pharmacotherapy, and mobile technology components, or a control intervention that includes smoking cessation counseling and pharmacotherapy, but no mobile technology components. The control condition represents an intensive standard of care and helps control for monitoring, counselor, time, and attention effects. 